Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-23T09:48:11.430Z Has data issue: false hasContentIssue false
  • English
  • Français

Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease

Published online by Cambridge University Press:  18 June 2010

Solveig Horstmann ,
Leila Budig ,
Humphrey Gardner ,
James Koziol ,
Michael Deuschle ,
Claudia Schilling  and
Simone Wagner
Solveig Horstmann
Affiliation:
Department of Neurology, Medical School, University of Heidelberg, Heidelberg, Germany
Leila Budig
Affiliation:
Department of Neurology, Medical School, University of Heidelberg, Heidelberg, Germany
Humphrey Gardner
Affiliation:
Novartis, Cambridge, MA, USA
James Koziol
Affiliation:
Scripps Research Institute, La Jolla, CA, U.S.A.
Michael Deuschle
Affiliation:
Central Institute of Mental Health, Mannheim, Germany
Claudia Schilling
Affiliation:
Central Institute of Mental Health, Mannheim, Germany
Simone Wagner*
Affiliation:
Department of Neurology, Medical School, University of Heidelberg, Heidelberg, Germany
*
Correspondence should be addressed to: Simone Wagner, Department of Neurology, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. Phone: +49-6221-567504; Fax: +49-6221-565461. Email: [email protected].
Get access

Abstract

Background: Deposition of amyloid β in senile plaques and in cerebral blood vessels is one hallmark of the pathogenesis of Alzheimer's disease (AD). The ability of several matrix metalloproteinases (MMPs) to degrade amyloid precursor protein leading to aggregation of amyloid β, as well as the increased expression of MMPs in post mortem brain tissue of Alzheimer's patients, indicate that MMPs play an important role in the pathogenesis of AD.

Methods: We investigated levels of MMP-2,-3,-9 and -10 in plasma and cerebrospinal fluid (CSF) of AD patients (n = 14) by gelatin and casein zymography. Comparisons between AD patients and controls relative to levels of MMP-2, MMP-3, MMP-9, and MMP-10 were made with Wilcoxon rank statistics. Pearson correlations were computed as measures of association.

Results: MMP-3 in AD was significantly elevated in plasma (p = 0.006) and there was a trend towards increase in CSF (p = 0.05). MMP-2 in CSF of AD patients was significantly decreased (p = 0.02) while levels in plasma remained unchanged. MMP-9 and MMP-10 could not be detected in CSF; MMP-10 was unchanged in plasma, but MMP-9 was significantly decreased (p = 0.02).

Conclusions: These findings constitute further evidence for the important role of MMPs in the pathogenesis of AD.

Keywords

matrix metalloproteinasesAlzheimer's diseasedementia
Type
Research Article
Information
International Psychogeriatrics , Volume 22 , Special Issue 6: Focus on training in psychogeriatrics , September 2010 , pp. 966 - 972
Copyright
Copyright © International Psychogeriatric Association 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adair, J. C. et al. (2004). Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke, 35, e159–162.CrossRefGoogle ScholarPubMed
Alvarez-Sabin, J. et al. (2004). Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke, 35, 1316–22.CrossRefGoogle ScholarPubMed
Backstrom, J. R., Lim, G. P., Cullen, M. J. and Tokes, Z. A. (1996). Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1–40). Journal of Neuroscience, 16, 79101–799.CrossRefGoogle ScholarPubMed
Bar-Or, A. et al. (2003). Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain, 126, 2738–2749.CrossRefGoogle ScholarPubMed
Beuche, W., Yushchenko, M., Mader, M., Maliszewska, M., Felgenhauer, K. and Weber, F. (2000). Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport, 11, 3419–3422.CrossRefGoogle ScholarPubMed
Beyzade, S., Zhang, S., Wong, Y. K., Day, I. N., Eriksson, P. and Ye, S. (2003). Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. Journal of the American College of Cardiology, 41, 2130–2137.CrossRefGoogle ScholarPubMed
Campbell, I. L. and Pagenstecher, A. (1999). Matrix metalloproteinases and their inhibitors in the nervous system: the good, the bad and the enigmatic. Trends in Neurosciences, 22, 285–287.CrossRefGoogle ScholarPubMed
Deb, S., Wenjun Zhang, J. and Gottschall, P. E. (2003). Beta-amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes. Brain Research, 970, 205–213.CrossRefGoogle ScholarPubMed
Flex, A. et al. (2006). Analysis of functional polymorphisms of metalloproteinase genes in persons with vascular dementia and Alzheimer's disease. Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 61, 1065–1069.CrossRefGoogle ScholarPubMed
Helbecque, N., Hermant, X., Cottel, D. and Amouyel, P. (2003). The role of matrix metalloproteinase-9 in dementia. Neuroscience Letters, 350, 181–183.CrossRefGoogle ScholarPubMed
Helbecque, N., Cottel, D., Hermant, X. and Amouyel, P. (2007). Impact of the matrix metalloproteinase MMP-3 on dementia. Neurobiology of Aging, 28, 1215–1220.CrossRefGoogle ScholarPubMed
Hofman, A. et al. (1997). Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet, 349, 151–154.CrossRefGoogle ScholarPubMed
Horstmann, S., Kalb, P., Koziol, J., Gardner, H. and Wagner, S. (2003). Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke, 34, 2165–2170.CrossRefGoogle ScholarPubMed
Lorenzl, S. et al. (2003a). Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. Journal of the Neurological Science, 207, 71–76.CrossRefGoogle ScholarPubMed
Lorenzl, S. et al. (2003b). Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochemistry International, 43, 191–196.CrossRefGoogle ScholarPubMed
Lorenzl, S., Buerger, K., Hampel, H. and Beal, M. F. (2008). Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. International Psychogeriatrics, 20, 67–76.CrossRefGoogle ScholarPubMed
Martin-Aragon, S. et al. (2009). Metalloproteinase's activity and oxidative stress in mild cognitive impairment and Alzheimer's disease. Neurochemical Research, 34, 373–378.CrossRefGoogle ScholarPubMed
McGeer, E. G. and McGeer, P. L. (1998). The importance of inflammatory mechanisms in Alzheimer disease. Experimental Gerontology, 33, 371–378.CrossRefGoogle ScholarPubMed
Montaner, J. et al. (2001). Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke, 32, 1759–1766.CrossRefGoogle ScholarPubMed
Mrak, R. E. and Griffin, W. S. (2007). Common inflammatory mechanisms in Lewy body disease and Alzheimer disease. Journal of Neuropathology and Experimental Neurology, 66, 683–686.CrossRefGoogle ScholarPubMed
Pollanen, P. J. et al. (2002). Coronary artery calcification is related to functional polymorphism of matrix metalloproteinase 3: the Helsinki Sudden Death Study. Atherosclerosis, 164, 329–335.CrossRefGoogle ScholarPubMed
Pollanen, P. J. et al. (2005). Matrix metalloproteinase3 and 9 gene promoter polymorphisms: joint action of two loci as a risk factor for coronary artery complicated plaques. Atherosclerosis, 180, 73–78.CrossRefGoogle ScholarPubMed
Pozzi, A., Moberg, P. E., Miles, L. A., Wagner, S., Soloway, P. and Gardner, H. A. (2000). Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proceedings of the National Academies of Sciences, 97, 2202–2207.CrossRefGoogle ScholarPubMed
Reitz, C. et al. (2008). Matrix metalloproteinase 3 haplotypes and dementia and Alzheimer's disease: the Rotterdam Study. Neurobiology of Aging, 29, 874–881.CrossRefGoogle ScholarPubMed
Roher, A. E., Kasunic, T. C., Woods, A. S., Cotter, R. J., Ball, M. J. and Fridman, R. (1994). Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A. Biochemical and Biophysical Research Communication, 205, 1755–1761CrossRefGoogle ScholarPubMed
Saarela, M. S. et al. (2004). Interaction between matrix metalloproteinase 3 and the epsilon4 allele of apolipoprotein E increases the risk of Alzheimer's disease in Finns. Neuroscience Letters, 367, 336–339.CrossRefGoogle ScholarPubMed
Thorns, V., Walter, G. F. and Thorns, C. (2003). Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer Research, 23, 3937–3944.Google ScholarPubMed
White, A. R. et al. (2006). Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. Journal of Biological Chemistry, 281, 17670–17680.CrossRefGoogle ScholarPubMed
Woessner, J. F. Jr. (1991). Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB Journal, 5, 2145–2154.CrossRefGoogle ScholarPubMed
Yoshiyama, Y., Asahina, M. and Hattori, T. (2000). Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain. Acta Neuropathologica, 99, 91–95.CrossRefGoogle ScholarPubMed